Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retatrutide in Type 2 Diabetes and Renal Impairment
NCT06297603Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Mar 2024
- Primary completion
- Oct 2026
- Modality
- Peptides, Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial of retatrutide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from Baseline in Hemoglobin A1c (HbA1c) at 52 weeks. Started Mar 2024; status: active, not recruiting.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06297603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06297603.